Scribe Therapeutics — Third Quarter 2026 Earnings Summary

Scribe Therapeutics reported third-quarter 2026 financial results, recording a net loss of $9.9 million and holding $174.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026. The company completed an upsized initial public offering in July 2026, raising approximately $155.5 million in aggregate gross proceeds, which extends its funding runway into the first half of 2029. Clinical progress includes ongoing enrollment in the first-in-human Phase 1 trial for STX-1150, an epigenetic silencing therapy targeting LDL-C lowering, with initial data expected in the first half of 2027. Additionally, Scribe expanded its strategic collaboration with Sanofi to include access to its ELXR epigenetic silencing technology alongside its existing gene-editing platform.